07:00 , Mar 24, 2014 |  BC Week In Review  |  Company News

Qiagen sales and marketing update

Qiagen launched QuantiFeron-TB Gold In-Tube blood test in China to diagnose Mycobacterium tuberculosis infection. The test was approved earlier this year by the China Food and Drug Administration (CFDA). Qiagen is also approved in the...
08:00 , Jan 16, 2012 |  BC Week In Review  |  Company News

Qiagen, Max Planck Institute for Infection Biology deal

Qiagen and the institute partnered to develop and commercialize a diagnostic test to assess the risk of subjects with latent tuberculosis (TB) developing active TB disease in their lifetime. Both parties will collect, analyze and...
07:00 , Sep 5, 2011 |  BC Week In Review  |  Company News

Cellestis, Qiagen deal

Qiagen completed its acquisition of diagnostics company Cellestis for A$3.80 per share. The price values Cellestis at about A$359 million ($382.3 million) (see BioCentury, July 18). Cellestis Ltd. , Carnegie, Australia   Qiagen N.V. (Xetra:QIA;...
07:00 , Jul 18, 2011 |  BC Week In Review  |  Company News

Cellestis, Qiagen deal

Qiagen increased its offer to acquire diagnostics company Cellestis to A$3.80 per share in cash from A$3.55. The price values Cellestis at about A$359 million ($374 million) and is a 27% premium to Cellestis' close...
07:00 , Jul 18, 2011 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Amgen Inc. (NASDAQ:AMGN) was off $0.63 to $55.05 on a newsy Friday. The European Commission approved Xgeva denosumab to prevent skeletal-related events in adults with bone metastases from solid tumors. Meanwhile, the company...
00:18 , Jul 12, 2011 |  BC Extra  |  Company News

Qiagen bumps up Cellestis offer

Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN) increased its proposal to acquire Australian diagnostics company Cellestis Ltd. (ASX:CST) to A$3.80 per share, or about A$359 million (US$374 million) in cash. The new price is 7% above the original...
07:00 , Apr 11, 2011 |  BC Week In Review  |  Company News

Cellestis, Qiagen deal

Qiagen will acquire Australian diagnostics company Cellestis for A$3.55 per share or A$341 million ($354.4 million) in cash. The price is an 18% premium to Cellestis' close of A$3 on April 1, before the deal...
07:00 , Apr 11, 2011 |  BioCentury  |  Finance

Regulatory milestones

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) added $2.38 to $102.38 last week after submitting regulatory applications to FDA and EMA for Soliris eculizumab to treat atypical hemolytic uremic syndrome (aHUS). Soliris is already approved to treat paroxysmal...
00:08 , Apr 5, 2011 |  BC Extra  |  Company News

Qiagen to acquire Cellestis

Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN) will acquire Australian diagnostics company Cellestis Ltd. (ASX:CST) for A$3.55 per share or A$341 million ($354.4 million) in cash. The price is an 18% premium to Cellestis' close of A$3 on...
07:00 , Sep 9, 2010 |  BC Innovations  |  Tools & Techniques

Identifying TB carriers at risk

More than 2 billion individuals worldwide are infected with latent tuberculosis and about 10% of the cases will progress to active disease. The problem is that current tests cannot identify which individuals will progress. Now,...